PharmaCyte Biotech Retains Industry Expert to Monitor Short Sellers and Market Makers
October 01 2015 - 9:25AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell in a Box ®, announced today that BUYINS.NET, a
leading provider of Regulation SHO compliance monitoring, short
sale trading statistics and market integrity surveillance, has
initiated coverage on Pharmacyte Biotech after releasing the latest
short sale data through September 29, 2015. BUYINS.NET will monitor
the market makers of PharmaCyte Biotech’s stock daily for
compliance with fair market-making requirements.
The SEC adopted Regulation SHO in 2005 to update short sale
regulation in light of numerous market developments since short
sale regulation was first adopted and to address concerns regarding
persistent failures to deliver and potentially abusive “naked”
short selling. Due to continued concerns about failures to deliver,
and to promote market stability and preserve investor confidence,
the SEC has amended Regulation SHO several times since 2005 to
eliminate certain exceptions, strengthen certain requirements and
reintroduce a price test restriction.
Regulation SHO requires bona-fide market-making activities to
include making purchases and sales in roughly comparable amounts.
The SEC has stated that bona-fide market-making does not include
activity that is related to speculative selling strategies for
investment purposes of the broker-dealer and is disproportionate to
the usual market making patterns or practices of the broker-dealer
in that security. Likewise, where a market-maker posts continually
at or near the best offer, but does not also post at or near the
best bid, the market-maker's activities would not generally qualify
as bona-fide market-making. Moreover, a market-maker that
continually executes short sales away from its posted quotes would
generally not be considered to be engaging in bona-fide
market-making.
About BUYINS.NET
BUYINS.NET monitors trading in all US stocks in real time and
maintains massive databases of short sale and naked short sale time
and sales data, short squeeze trigger prices, market-maker price
movements, shareholder data, statistical data on earnings, sector
correlation, seasonality, hedge fund trading strategies and
comparable valuations.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company
focused on developing and preparing to commercialize treatments for
cancer and diabetes based upon a proprietary cellulose-based live
cell encapsulation technology known as “Cell-in-a-Box®”. This
unique and patented technology will be used as a platform upon
which treatments for several types of cancer and diabetes are being
developed.
PharmaCyte Biotech’s treatment for cancer involves encapsulating
genetically modified live cells capable of converting an inactive
chemotherapy drug (ifosfamide) into its active or “cancer-killing”
form. These encapsulated live cells are placed as close to a
cancerous tumor as possible. Once implanted in a patient,
ifosfamide is given intravenously at one-third the normal dose. The
ifosfamide is carried by the circulatory system to where the
encapsulated cells have been placed. When ifosfamide, which is
normally activated in the liver, comes in contact with the
encapsulated live cells, activation of the drug takes place at the
source of the cancer without any side effects from the
chemotherapy. This “targeted chemotherapy” has proven remarkably
effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer,
PharmaCyte Biotech is developing a treatment for Type 1 diabetes
and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to
encapsulate a human cell line which has been genetically engineered
to produce, store and secrete insulin at levels in proportion to
the levels of blood sugar in the human body. The encapsulation will
be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements
regarding PharmaCyte Biotech and its future events and results that
involve inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to PharmaCyte Biotech or its
management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of
PharmaCyte Biotech, could cause actual results to differ materially
from those set forth in the forward-looking statements. They
include PharmaCyte Biotech's ability to continue as a going
concern, delays or unsuccessful results in preclinical and clinical
trials, flaws or defects regarding its product candidates, changes
in relevant legislation or regulatory requirements, uncertainty of
protection of PharmaCyte Biotech’s intellectual property and
PharmaCyte Biotech’s continued ability to raise capital. PharmaCyte
Biotech does not assume any obligation to update any of these
forward-looking statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com